Session » 5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)
-
Abstract Number: 2840
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
-
Abstract Number: 2841
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
-
Abstract Number: 2842
Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control
-
Abstract Number: 2843
Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects